| Matthew Skaggs, CRNA | |
|
79711 467th Ave, Arcadia, NE 68815 | |
| (308) 379-4556 | |
| Not Available |
| Full Name | Matthew Skaggs |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 79711 467th Ave, Arcadia, Nebraska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548678162 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 101252 (Nebraska) | Primary |
| Entity Name | Anesthesia Group Of Grand Island, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346216793 PECOS PAC ID: 1850377110 Enrollment ID: O20040628000198 |
News Archive
According to figures released by the Alzheimer's Association, deaths from Alzheimer's and other forms of dementia rose 68 percent between 2000 and 2010.
For decades, aspirin has been widely used to reduce the risk of cardiovascular problems. Now, a team led by a University of Florida Health researcher has found that aspirin may provide little or no benefit for certain patients who have plaque buildup in their arteries.
Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Ablation of the Locus Coeruleus (LC) Increases Oxidative Stress in Tg-2576 Transgenic But Not Wild-type Mice" in the International Journal of Alzheimer Disease.
› Verified 5 days ago
| Entity Name | Sonno Anesthesia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225331978 PECOS PAC ID: 7315127701 Enrollment ID: O20110201000828 |
News Archive
According to figures released by the Alzheimer's Association, deaths from Alzheimer's and other forms of dementia rose 68 percent between 2000 and 2010.
For decades, aspirin has been widely used to reduce the risk of cardiovascular problems. Now, a team led by a University of Florida Health researcher has found that aspirin may provide little or no benefit for certain patients who have plaque buildup in their arteries.
Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Ablation of the Locus Coeruleus (LC) Increases Oxidative Stress in Tg-2576 Transgenic But Not Wild-type Mice" in the International Journal of Alzheimer Disease.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Skaggs, CRNA 79711 467th Ave, Arcadia, NE 68815 Ph: () - | Matthew Skaggs, CRNA 79711 467th Ave, Arcadia, NE 68815 Ph: (308) 379-4556 |
News Archive
According to figures released by the Alzheimer's Association, deaths from Alzheimer's and other forms of dementia rose 68 percent between 2000 and 2010.
For decades, aspirin has been widely used to reduce the risk of cardiovascular problems. Now, a team led by a University of Florida Health researcher has found that aspirin may provide little or no benefit for certain patients who have plaque buildup in their arteries.
Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Ablation of the Locus Coeruleus (LC) Increases Oxidative Stress in Tg-2576 Transgenic But Not Wild-type Mice" in the International Journal of Alzheimer Disease.
› Verified 5 days ago